How Do I Understand Fatty Liver Test Results and Fibrosis Risk?

October 18, 2026

An ultrasound showing fatty liver does not reveal liver scarring on its own. Liver enzymes show possible injury, not the stage of disease. A FIB-4 score combines age, AST, ALT, and platelets to sort fibrosis risk; low scores often remain in primary care, while higher scores call for elastography, repeat testing, or liver-specialist assessment.

One image. Several unanswered questions.

The useful order is simple: confirm what the test can say, calculate fibrosis risk, then choose the next test only if the risk screen calls for it.

My ultrasound found fatty liver but my liver enzymes are normal. Is that serious?

Normal liver enzymes do not rule out fibrosis, and an ultrasound finding alone cannot show whether scarring is present. The National Institute of Diabetes and Digestive and Kidney Diseases states that routine ultrasound, CT, and MRI can show liver fat but cannot show inflammation or fibrosis.

That creates a clean distinction. Ultrasound answers whether fat is visible. It does not answer whether fatty liver has become steatohepatitis or advanced fibrosis.

Normal ALT and AST are useful facts. They are not a clearance certificate. The 2024 EASL-EASD-EASO clinical practice guideline recommends blood-based fibrosis scores, alone or paired with imaging, because they detect fibrosis more accurately than ALT and AST alone.

The first appointment after an ultrasound is often about sorting the cause as well as the risk. NIDDK notes that liver fat can also relate to alcohol-associated liver disease, rapid weight loss or malnutrition, certain medicines, toxins, and rare genetic diseases. A sound review does not treat every bright ultrasound image as the same condition.

Risk factors shape the next step. NIDDK lists overweight or obesity, insulin resistance or type 2 diabetes, abnormal blood fats, and metabolic syndrome among the factors linked with fatty liver disease. The question is not whether the scan looks alarming. The question is whether the full pattern points toward fibrosis risk.

What do high ALT and AST levels mean when you have fatty liver?

High ALT and AST signal that liver cells are releasing enzymes into the blood, but the values do not measure fibrosis by themselves. NIDDK explains that elevated ALT and AST can lead clinicians to suspect fatty liver disease, while routine blood results can also help calculate scores that identify or rule out advanced scarring.

ALT and AST are aminotransferases. They describe a current laboratory signal. Fibrosis describes accumulated scar tissue. Injury is not the same as scarring.

Persistent elevation changes the discussion. The AASLD Practice Guidance from 2023 says direct gastroenterology or hepatology referral should be considered when aminotransferases remain above normal for more than 6 months. The same guidance treats a FIB-4 score above 2.67 as a reason to consider direct referral.

A useful appointment question is: what else could explain these enzyme results? The answer rests on the broader medical review, not a single number. Another useful question is whether the current blood work includes platelet count, since FIB-4 needs it.

Result pattern	What the evidence supports
Fat seen on routine imaging	NIDDK says imaging can show fat but cannot show inflammation or fibrosis.
ALT or AST above normal for more than 6 months	AASLD 2023 says direct gastroenterology or hepatology referral should be considered.
FIB-4 below 1.3	AASLD 2023 says the likelihood of advanced fibrosis is low enough for periodic follow-up in primary care in many cases.
FIB-4 of 1.3 or higher	AASLD 2023 calls for secondary assessment, often elastography, an Enhanced Liver Fibrosis blood test, or referral for risk sorting.
FIB-4 above 2.67	AASLD 2023 says direct specialist referral should be considered.

Numbers are signals. Their sequence matters more than any isolated result.

What is a FIB-4 score, and can I calculate it from my blood tests?

FIB-4 is a noninvasive fibrosis-risk score calculated from age, AST, ALT, and platelet count. The EASL-EASD-EASO guideline from 2024 gives the formula as age multiplied by AST, divided by platelet count multiplied by the square root of ALT; age is in years, AST and ALT are in U/L, and platelet count is in 10⁹/L.

The calculation is easy to state. Its meaning needs context.

Under the AASLD Practice Guidance from 2023, a FIB-4 below 1.3 indicates a low likelihood of advanced fibrosis and usually permits periodic primary-care follow-up. For people without prediabetes or type 2 diabetes who have 1 or 2 metabolic risk factors, AASLD 2023 advises reassessment every 2 to 3 years. For people with prediabetes, type 2 diabetes, or at least 2 metabolic risk factors, it advises reassessment every 1 to 2 years.

A score of 1.3 or higher is not a diagnosis of advanced fibrosis. It is a fork in the road. AASLD 2023 favors vibration-controlled elastography, often called FibroScan, or an Enhanced Liver Fibrosis blood test as the next risk check. The EASL-EASD-EASO guideline from 2024 also supports a two-step path: FIB-4 first, then liver elastography.

Age changes the reading. AASLD 2023 says FIB-4 has low accuracy in people under age 35 and recommends a cutoff above 2.0 for people older than 65. The 2024 EASL-EASD-EASO guideline also flags limited accuracy in the middle range from 1.3 to 2.67, in type 2 diabetes, and at the younger and older ends of age.

A low-risk screen is useful, not absolute. EASL-EASD-EASO reported in 2024 that FIB-4 below 1.3 can miss about 10% of people with advanced fibrosis. That is why a score belongs beside the scan, enzyme pattern, platelet count, metabolic risks, and the clinician's assessment.

FibroScan does not replace thought. It adds a different measurement: stiffness. NIDDK explains that increased stiffness on elastography can be a sign of fibrosis. Liver biopsy remains the test that can prove steatohepatitis and clearly show severity, though NIDDK states it is not recommended for every person with suspected fatty liver disease.

The clearest discussion asks three things: What is the FIB-4 score? Does age alter its cutoff? Does the result call for elastography or specialist review?

Frequently Asked Questions

Do I need a FibroScan or liver biopsy after a fatty liver diagnosis?

Not every person with fatty liver needs either test. NIDDK states that elastography measures liver stiffness, which can signal fibrosis, while biopsy is the only test that proves steatohepatitis and clearly shows severity. AASLD guidance from 2023 uses FIB-4 of 1.3 or higher as a reason for secondary assessment, often with FibroScan, an Enhanced Liver Fibrosis blood test, or referral.

How often should liver enzymes and fibrosis risk be checked?

AASLD guidance from 2023 places the timing on metabolic risk. It advises reassessing FIB-4 every 2 to 3 years for people without prediabetes or type 2 diabetes who have 1 or 2 metabolic risk factors, and every 1 to 2 years for people with prediabetes, type 2 diabetes, or at least 2 metabolic risk factors. The clinician also interprets liver enzymes in the context of the full evaluation.

What symptoms could mean fatty liver has progressed to scarring?

Symptoms do not reliably mark progression. NIDDK says fatty liver disease often has few or no symptoms, including after cirrhosis develops. Fatigue or discomfort in the upper-right abdomen can occur, but new symptoms and changing test results need clinical evaluation rather than self-diagnosis.

A quiet liver still leaves clues. The task is to read them in order.

Sources

Disclaimer: This article is for general information only and is not medical advice. It is not a substitute for diagnosis or treatment by a qualified healthcare professional. Always speak to your doctor before acting on anything you read here.